Moderna's Q4 Sales Plummet; Company Bets on New Vaccine for 10% Growth by 2026

Humana Reports Wider Quarterly Loss, Expects 2026 Earnings Decline

Humana reported a wider fourth-quarter loss as medical costs continue to rise and said it expects a sharp decline in 2026 earnings due to lower quality ratings of its Medicare plans.

Markets★★Similarity: 63% · 68d ago

AstraZeneca Reiterates $80 Billion Revenue Goal for 2030

CEO Pascal Soriot said in a call with reporters on Tuesday that the group’s confidence in reaching $80 billion in revenue in 2030 was growing.

Markets★★★Similarity: 63% · 66d ago

Sanofi Shares Fall After CEO Change

Belen Garijo will succeed Paul Hudson as CEO following a string of clinical setbacks at the drugmaker.

Markets★★Similarity: 62% · 66d ago

Adyen Shares Hit Two-Year Low After Revenue Miss, Flat Adjusted Earnings Forecast

Revenue failed to meet consensus expectations and the company forecast flat Ebitda margins growth for the new year.

Moderna's Q4 Sales Plummet; Company Bets on New Vaccine for 10% Growth by 2026

Read More On

Related Articles

Humana Reports Wider Quarterly Loss, Expects 2026 Earnings Decline

AstraZeneca Reiterates $80 Billion Revenue Goal for 2030

Sanofi Shares Fall After CEO Change

Adyen Shares Hit Two-Year Low After Revenue Miss, Flat Adjusted Earnings Forecast

Moderna's Q4 Sales Plummet; Company Bets on New Vaccine for 10% Growth by 2026

Read More On

Related Articles

Humana Reports Wider Quarterly Loss, Expects 2026 Earnings Decline

AstraZeneca Reiterates $80 Billion Revenue Goal for 2030

Sanofi Shares Fall After CEO Change

Adyen Shares Hit Two-Year Low After Revenue Miss, Flat Adjusted Earnings Forecast